Use of nanotechnology to develop multi-drug inhibitors for cancer therapy

Journal of Nanomedicine and Nanotechnology

Volumn 4, Issue 6, 2013, Pages

  Gowda, Raghavendra ^a   Jones, Nathan R ^a   Banerjee, Shubhadeep ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer therapy; Multi drug inhibitors; Multi target inhibitors; Nanoliposomes; Nanotechnology

Indexed keywords

ANTINEOPLASTIC AGENT; CABOZANTINIB; CARBOPLATIN; CRIZOTINIB; CYTARABINE; DAUNORUBICIN; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LENVATINIB; LESTAURTINIB; LIPOSOME; MATRIX METALLOPROTEINASE; METHOTREXATE; MITOMYCIN; MOTESANIB; NILOTINIB; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; ZOLEDRONIC ACID; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANGIOMYOLIPOMA; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MICELLE; NANOTECHNOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); THYROID TUMOR; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 84893397550     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000184     Document Type: Article

References (241)

1. Smalley KS, Herlyn M (2006) Towards the targeted therapy of melanoma. Mini Rev Med Chem 6: 387-393.
2. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347-360.
3. Langer R (1998) Drug delivery and targeting. Nature 392: 5-10.
4. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, et al. (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251-255.
5. Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, et al. (2013) Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol 182: 1151-1162.
6. Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ (2013) Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol 779: 223-255.
7. Banaszynski M, Kolesar JM (2013) Vemurafenib and ipilimumab: new agents for metastatic melanoma. Am J Health Syst Pharm 70: 1205-1210.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
10. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1423-1432.
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
12. Kudchadkar R, Paraiso KH, Smalley KS (2012) Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 18: 124-131.
13. Sullivan RJ, Flaherty KT (2013) Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49: 1297-1304.
14. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
15. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
16. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, et al. (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67: 2649-2656.
17. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
18. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
19. Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561-573.
20. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851.
21. Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, et al. (2007) Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation; research in biological diversity 75: 843-852.
22. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, et al. (2005) Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP-and HGF-mediated signaling networks. Oncogene 24: 5053-5068.
23. Coltrera MD, Wang J, Porter PL, Gown AM (1995) Expression of plateletderived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 55: 2703-2708.
24. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, et al. (2001) Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61: 8135-8142.
25. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, et al. (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011.
26. Petrelli A, Valabrega G (2009) Multitarget drugs: the present and the future of cancer therapy. Expert Opin Pharmacother 10: 589-600.
27. Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11: 685-696.
28. Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, et al. (2007) Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 3363-3369.
29. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
30. Massicotte MH, Borget I, Broutin S, Baracos VE, Leboulleux S, et al. (2013) Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo controlled study. The Journal of clinical endocrinology and metabolism.
31. Rajendra R, Jones RL, Pollack SM (2013) Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. Onco Targets Ther 6: 217-222.
32. Vrdoljak E, Rini B, Schmidinger M, Omrčen T, Torday L, et al. (2013) Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 24: 431-440.
33. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730.
34. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.
35. Zimmermann GR, Lehár J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42.
36. Berenbaum MC (1985) The expected effect of a combination of agents: the general solution. J Theor Biol 114: 413-431.
37. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331-385.
38. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, et al. (2009) CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28: 85-94.
39. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
40. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
41. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
42. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551.
43. Blay JY, Reichardt P (2009) Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert Rev Anticancer Ther 9: 831-838.
44. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, et al. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer therapeutics 6: 3314-3322.
45. Janoueix-Lerosey I, Schleiermacher G, Delattre O (2010) Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 29: 1566-1579.
46. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, et al. (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30: 2829-2836.
47. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, et al. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626.
48. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671.
49. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, et al. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108: 3262-3270.
50. Traynor K (2013) Cabozantinib approved for advanced medullary thyroid cancer. Am J Health Syst Pharm 70: 88.
51. Lee RJ, Smith MR (2013) Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 19: 90-98.
52. Vaishampayan U (2013) Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep 15: 76-82.
53. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, et al. (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 3126-3132.
54. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, et al. (2005) Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer 12 Suppl 1: S1-7.
55. Greco F, Vicent MJ (2009) Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 61: 1203-1213.
56. Logman JF, Heeg BM, Botteman MF, Kaura S, van Hout BA (2010) Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol 21: 1529-1536.
57. Parhi P, Mohanty C, Sahoo SK (2012) Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 17: 1044-1052.
58. Shi J, Votruba AR, Farokhzad OC, Langer R (2010) Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 10: 3223-3230.
59. Chiang CT, Yeh PY, Gao M, Chen CW, Yeh LC, et al. (2010) Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Lett 298: 195-203.
60. Hubensack M, Müller C, Höcherl P, Fellner S, Spruss T, et al. (2008) Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134: 597-607.
61. Lancet JE, Baer MR, Duran GE, List AF, Fielding R, et al. (2009) A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 33: 1055-1061.
62. Tanabe M, Ito Y, Tokudome N, Sugihara T, Miura H, et al. (2009) Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer 16: 301-306.
63. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, et al. (2007) Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 1768: 678-687.
64. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, et al. (2008) Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 68: 7638-7649.
65. Tran MA, Watts RJ, Robertson GP (2009) Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res 22: 388-399.
66. Hussain M, Beale G, Hughes M, Akhtar S (2002) Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-coglycolide) microsphere formulations for potential combination therapy in cancer. Int J Pharmaceutics 234: 129-138.
67. Vale CL, Tierney J, Bull SJ, Symonds PR (2012) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 8: CD003915.
68. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Husted S, et al. (1990) Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 8: 119-127.
69. Moreno Garcia V, Basu B, Molife LR, Kaye SB (2012) Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 18: 3750-3761.
70. Hu CM, Zhang L (2012) Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 83: 1104-1111.
71. Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 14: 150-163.
72. Grodzinski P, Silver M, Molnar LK (2006) Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn 6: 307-318.
73. McNeil SE (2005) Nanotechnology for the biologist. J Leukoc Biol 78: 585-594.
74. Singh S, Sharma A, Robertson GP (2012) Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res 72: 5663-5668.
75. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
76. Aryal S, Hu CM, Zhang L (2011) Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm 8: 1401-1407.
77. Khdair A, Handa H, Mao G, Panyam J (2009) Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 71: 214-222.
78. Jain KK (2005) Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat 4: 407-416.
79. Zhao P, Astruc D (2012) Docetaxel nanotechnology in anticancer therapy. ChemMedChem 7: 952-972.
80. Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM (2011) A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine 6: 2963-2979.
81. Sultana Y, Maurya DP, Iqbal Z, Aqil M (2011) Nanotechnology in ocular delivery: current and future directions. Drugs Today (Barc) 47: 441-455.
82. Venkatesan Perumal SB, Das S, Sen RK, Mandal M (2011) Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model. Cancer Nanotech 2: 67-79.
83. Muthu MS, Rajesh CV, Mishra A, Singh S (2009) Stimulus-responsive targeted nanomicelles for effective cancer therapy. Nanomedicine (Lond) 4: 657-667.
84. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338: 903-910.
85. Koo H, Huh MS, Sun IC, Yuk SH, Choi K, et al. (2011) In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res 44: 1018-1028.
86. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, et al. (2011) Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci 102: 1247-1252.
87. Sánchez-Moreno P, Boulaiz H, Ortega-Vinuesa JL, Peula-García JM, Aránega A (2012) Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells. Int J Mol Sci 13: 4906-4919.
88. Samarasinghe RM, Gibbons J, Kanwar RK, Kanwar JR (2012) Nanotechnology based platforms for survivin targeted drug discovery. Expert Opin Drug Discov 7: 1083-1092.
89. Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, et al. (2011) Search for dilepton resonances in pp collisions at â̂šs=7 TeV with the ATLAS detector. Phys Rev Lett 107: 272002.
90. Huang Y, He S, Cao W, Cai K, Liang XJ (2012) Biomedical nanomaterials for imaging-guided cancer therapy. Nanoscale 4: 6135-6149.
91. Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, et al. (2012) Nanotechnology-based approaches in anticancer research. Int J Nanomedicine 7: 4391-4408.
92. Kumar P, Gulbake A, Jain SK (2012) Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy. Crit Rev Ther Drug Carrier Syst 29: 355-419.
93. Wang XM, Liu CM, Zhang CR, Xu XG, Fu SB (2009) [Functional significance of TGF-beta1 signal transduction pathway in oral squamous cell carcinoma]. Zhonghua Zhong Liu Za Zhi 31: 28-32.
94. Heneweer C, Gendy SE, Peñate-Medina O (2012) Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther Deliv 3: 645-656.
95. Egusquiaguirre SP, Igartua M, Hernández RM, Pedraz JL (2012) Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 14: 83-93.
96. Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30: 592-599.
97. Rouse BT (1982) Liposomes as carriers of antigens as well as other molecules involved in immunity. J Am Vet Med Assoc 181: 988-991.
98. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ (1997) Targeting gene therapy to cancer: a review. Oncol Res 9: 313-325.
99. Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol: 3-53.
100. Matsumura Y (2007) Preclinical and clinical studies of anticancer drugincorporated polymeric micelles. J Drug Target 15: 507-517.
101. Tarhini AA, Agarwala SS (2005) Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs 14: 885-892.
102. Guo P, Haque F, Hallahan B, Reif R, Li H (2012) Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther 22: 226-245.
103. Sun M, Su X, Ding B, He X, Liu X, et al. (2012) Advances in nanotechnologybased delivery systems for curcumin. Nanomedicine (Lond) 7: 1085-1100.
104. Mura S, Couvreur P (2012) Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 64: 1394-1416.
105. Sanna V, Sechi M (2012) Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine 8 Suppl 1: S31-36.
106. Tiwari M (2012) Nano cancer therapy strategies. J Cancer Res Ther 8: 19-22.
107. Rakowski JA, Ahmad S, Holloway RW (2012) Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts. Expert Rev Anticancer Ther 12: 31-40.
108. Grenader T, Rosengarten O, Isacson R, Plotkin Y, Gabizon A (2012) Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin. World J Clin Oncol 3: 137-141.
109. Gao Z, Zhang L, Sun Y (2012) Nanotechnology applied to overcome tumor drug resistance. J Control Release 162: 45-55.
110. Dancey JE, Bedard PL, Onetto N, Hudson TJ (2012) The genetic basis for cancer treatment decisions. Cell 148: 409-420.
111. Stegh AH (2013) Toward personalized cancer nanomedicine-past, present, and future. Integr Biol (Camb) 5: 48-65.
112. Akhtar S, Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117: 3623-3632.
113. Kim WJ, Kim SW (2009) Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 26: 657-666.
114. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
115. Yagi N, Manabe I, Tottori T, Ishihara A, Ogata F, et al. (2009) A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res 69: 6531-6538.
116. Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, et al. (2008) Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 100: 109-120.
117. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, et al. (2008) Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100: 359-372.
118. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, et al. (2009) Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8: 1027-1034.
119. Bhavsar D, Subramanian K, Sethuraman S, Krishnan UM (2012) Translational siRNA therapeutics using liposomal carriers: prospects & challenges. Curr Gene Ther 12: 315-332.
120. Saad M, Garbuzenko OB, Minko T (2008) Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 3: 761-776.
121. Tran MA, Smith CD, Kester M, Robertson GP (2008) Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 14: 3571-3581.
122. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
123. Shim G, Han SE, Yu YH, Lee S, Lee HY, et al. (2011) Trilysinoyl oleylamidebased cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release 155: 60-66.
124. Kang SH, Cho HJ, Shim G, Lee S, Kim SH, et al. (2011) Cationic liposomal codelivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm Res 28: 3069-3078.
125. Xiao W, Chen X, Yang L, Mao Y, Wei Y, et al. (2010) Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharm 393: 119-126.
126. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP (2003) Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21: 3319-3329.
127. Kim JY, Shim G, Choi HW, Park J, Chung SW, et al. (2012) Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 33: 4424-4430.
128. Wong HL, Bendayan R, Rauth AM, Wu XY (2006) Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 116: 275-284.
129. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, et al. (2009) A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 119: 255-269.
130. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, et al. (2009) Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A 106: 7957-7961.
131. Wu J, Lu Y, Lee A, Pan X, Yang X, et al. (2007) Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10: 350-357.
132. Ichiki H, Hamasaki S, Nakasaki M, Ishida S, Yoshikawa A, et al. (2010) Relationship between hyperglycemia and coronary vascular resistance in nondiabetic patients. Int J Cardiol 141: 44-48.
133. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group (2009) Phase II trial of weekly nab (nanoparticle albuminbound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20: 449-453.
134. Zucker D, Andriyanov AV, Steiner A, Raviv U, Barenholz Y (2012) Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 160: 281-289.
135. Zucker D, Barenholz Y (2010) Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes. J Control Release 146: 326-333.
136. Abe K, Abgrall N, Aihara H, Ajima Y, Albert JB, et al. (2011) The T2K experiment. Nuclear Instruments & Methods in Physics Research Section a-Accelerators Spectrometers Detectors and Associated Equipment 659: 106-135.
137. Song S, Wientjes MG, Walsh C, Au JL (2001) Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 61: 6145-6150.
138. Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, et al. (2001) In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 7: 202-209.
139. Raitanen M, Rantanen V, Kulmala J, Helenius H, Grénman R, et al. (2002) Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. Int J Cancer 100: 238-243.
140. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, et al. (2006) Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5: 1854-1863.
141. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, et al. (2009) In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33: 129-139.
142. Harasym TO, Tardi PG, Harasym NL, Harvie P, Johnstone SA, et al. (2007) Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res 16: 361-374.
143. Sawant RR, Vaze OS, Rockwell K, Torchilin VP (2010) Palmitoyl ascorbatemodified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur J Pharm Biopharm 75: 321-326.
144. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q (2010) Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 74: 467-473.
145. Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M (2012) Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm 422: 229-237.
146. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, et al. (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436: 568-572.
147. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
148. Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y (2008) Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 70: 718-725.
149. Chen CH, Liu DZ, Fang HW, Liang HJ, Yang TS, et al. (2008) Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer. Biosci Biotechnol Biochem 72: 1586-1594.
150. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75: 1-18.
151. Mainardes RM, Silva LP (2004) Drug delivery systems: past, present, and future. Curr Drug Targets 5: 449-455.
152. Parveen S, Sahoo SK (2008) Polymeric nanoparticles for cancer therapy. J Drug Target 16: 108-123.
153. Cegnar M, Kristl J, Kos J (2005) Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert Opin Biol Ther 5: 1557-1569.
154. Akhter S, Ahmad I, Ahmad MZ, Ramazani F, Singh A, et al. (2013) Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets 13: 362-378.
155. Abolmaali SS, Tamaddon AM, Dinarvand R (2013) A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol 71: 1115-1130.
156. Men K, Liu W, Li L, Duan X, Wang P, et al. (2012) Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermosensitive hydrogel composite system. Nanoscale 4: 6425-6433.
157. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, et al. (2009) Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 9: 325-341.
158. Jain AK, Das M, Swarnakar NK, Jain S (2011) Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst 28: 1-45.
159. Tang MF, Lei L, Guo SR, Huang WL (2010) Recent progress in nanotechnology for cancer therapy. Chin J Cancer 29: 775-780.
160. Milane L, Duan Z, Amiji M (2011) Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm 8: 185-203.
161. Song XR, Cai Z, Zheng Y, He G, Cui FY, et al. (2009) Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37: 300-305.
162. Misra R, Sahoo SK (2011) Coformulation of doxorubicin and curcumin in poly(D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 8: 852-866.
163. Walter MV, Malkoch M (2012) Simplifying the synthesis of dendrimers: accelerated approaches. Chem Soc Rev 41: 4593-4609.
164. Baker JR Jr (2009) Dendrimer-based nanoparticles for cancer therapy. Hematology Am Soc Hematol Educ Program.
165. Bai S, Thomas C, Rawat A, Ahsan F (2006) Recent progress in dendrimerbased nanocarriers. Crit Rev Ther Drug Carrier Syst 23: 437-495.
166. Kaminskas LM, Boyd BJ, Porter CJ (2011) Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine (Lond) 6: 1063-1084.
167. Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, et al. (2012) Dendrimerbased postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 4: 130ra46.
168. Wijagkanalan W, Kawakami S, Hashida M (2011) Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm Res 28: 1500-1519.
169. Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57: 2215-2237.
170. Jain K, Kesharwani P, Gupta U, Jain NK (2010) Dendrimer toxicity: Let's meet the challenge. Int J Pharm 394: 122-142.
171. Hourani R, Kakkar A (2010) Advances in the elegance of chemistry in designing dendrimers. Macromol Rapid Commun 31: 947-974.
172. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK (2009) Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci 38: 185-196.
173. Svenson S, Tomalia DA (2005) Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev 57: 2106-2129.
174. Tekade RK, Dutta T, Gajbhiye V, Jain NK (2009) Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J Microencapsul 26: 287-296.
175. Kaneshiro TL, Lu ZR (2009) Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 30: 5660-5666.
176. Pablico-Lansigan MH, Situ SF, Samia AC (2013) Magnetic particle imaging: advancements and perspectives for real-time in vivo monitoring and imageguided therapy. Nanoscale 5: 4040-4055.
177. Hilger I, Kaiser WA (2012) Iron oxide-based nanostructures for MRI and magnetic hyperthermia. Nanomedicine (Lond) 7: 1443-1459.
178. Maas ML, Specht JP, Buckwalter KC, Gittler J, Bechen K (2008) Nursing home staffing and training recommendations for promoting older adults' quality of care and life: Part 1. Deficits in the quality of care due to understaffing and undertraining. Res Gerontol Nurs 1: 123-133.
179. Alexiou C, Tietze R, Schreiber E, Lyer S (2010) [Nanomedicine: Magnetic nanoparticles for drug delivery and hyperthermia-new chances for cancer therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53: 839-845.
180. Laurent S, Boutry S, Mahieu I, Vander Elst L, Muller RN (2009) Iron oxide based MR contrast agents: from chemistry to cell labeling. Curr Med Chem 16: 4712-4727.
181. Atmaca H, Karaca B, Uzunoglu S, Karabulut B, Sanli UA, et al. (2009) Synergistic Inhibition of Angiogenin by Combined Treatment with Gossypol and Cisplatin in a Human Ovarian Cancer Cell Line, Ovcar-3. Iubmb Life 61: 349-349.
182. Schwerdt JI, Goya GF, Calatayud MP, Hereñú CB, Reggiani PC, et al. (2012) Magnetic field-assisted gene delivery: achievements and therapeutic potential. Curr Gene Ther 12: 116-126.
183. Hsieh WJ, Liang CJ, Chieh JJ, Wang SH, Lai IR, et al. (2012) In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibodyconjugated dextran-coated iron oxide nanoparticles. Int J Nanomedicine 7: 2833-2842.
184. Tang C, Russell PJ, Martiniello-Wilks R, Rasko JE, Khatri A (2010) Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy? Stem Cells 28: 1686-1702.
185. Wang M, Thanou M (2010) Targeting nanoparticles to cancer. Pharmacol Res 62: 90-99.
186. Kievit FM, Zhang M (2011) Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res 44: 853-862.
187. CywiÅska MA, GrudziÅski IP (2012) [Modern toxicology of magnetic nanomaterials]. Rocz Panstw Zakl Hig 63: 247-256.
188. Mattheolabakis G, Rigas B, Constantinides PP (2012) Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 7: 1577-1590.
189. Namiki Y, Fuchigami T, Tada N, Kawamura R, Matsunuma S, et al. (2011) Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Acc Chem Res 44: 1080-1093.
190. Liu Y, Miyoshi H, Nakamura M (2007) Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 120: 2527-2537.
191. Puri A, Blumenthal R (2011) Polymeric lipid assemblies as novel theranostic tools. Acc Chem Res 44: 1071-1079.
192. Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, et al. (2007) Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl 46: 8836-8839.
193. Yu MK, Jeong YY, Park J, Park S, Kim JW, et al. (2008) Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl 47: 5362-5365.
194. Kumar A, Sahoo B, Montpetit A, Behera S, Lockey RF, et al. (2007) Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine 3: 132-137.
195. Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, et al. (2012) Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine 7: 1761-1779.
196. Shi X, Thomas TP, Myc LA, Kotlyar A, Baker JR Jr (2007) Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys 9: 5712-5720.
197. Rawat M, Singh D, Saraf S, Saraf S (2006) Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 29: 1790-1798.
198. Kataoka K, Harada A, Nagasaki Y (2001) Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 47: 113-131.
199. Zheng C, Qiao MX, Yan L, Hu HY, Chen DW (2007) [Recent advances in the study of dendrimers-based drug delivery systems]. Yao Xue Xue Bao 42: 924-929.
200. Blanco E, Kessinger CW, Sumer BD, Gao J (2009) Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 234: 123-131.
201. Li W, Feng S, Guo Y (2012) Tailoring polymeric micelles to optimize delivery to solid tumors. Nanomedicine (Lond) 7: 1235-1252.
202. Torchilin VP (2004) Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 61: 2549-2559.
203. Lee KS, Chung HC, Im SA, Park YH, Kim CS, et al. (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108: 241-250.
204. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, et al. (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelleformulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10: 3708-3716.
205. Zhu C, Jung S, Luo S, Meng F, Zhu X, et al. (2010) Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 31: 2408-2416.
206. Lee JH, Nan A (2012) Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012: 915375.
207. Katragadda U, Teng Q, Rayaprolu BM, Chandran T, Tan C (2011) Multi-drug delivery to tumor cells via micellar nanocarriers. Int J Pharm 419: 281-286.
208. Fan L, Li F, Zhang HT, Wang YK, Cheng C, et al. (2010) Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 31: 5634-5642.
209. Hu Q, Li W, Hu X, Hu Q, Shen J, et al. (2012) Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. Biomaterials 33: 6580-6591.
210. Wiradharma N, Tong YW, Yang YY (2009) Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 30: 3100-3109.
211. Oh JK, Drumright R, Siegwart DJ, Matyjaszewski K (2008) The development of microgels/nanogels for drug delivery applications. Progress in Polymer Science 33: 448-477.
212. Kabanov AV, Vinogradov SV (2009) Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed Engl 48: 5418-5429.
213. Phillips MA, Gran ML, Peppas NA (2010) Targeted Nanodelivery of Drugs and Diagnostics. Nano Today 5: 143-159.
214. Ganta S, Devalapally H, Shahiwala A, Amiji M (2008) A review of stimuliresponsive nanocarriers for drug and gene delivery. J Control Release 126: 187-204.
215. Qiu Y, Park K (2001) Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 53: 321-339.
216. Banerjee S, Sen K, Pal TK, Guha SK (2012) Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy. Int J Pharm 436: 786-797.
217. Sershen SR, Westcott SL, Halas NJ, West JL (2000) Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery. J Biomed Mater Res 51: 293-298.
218. Konishi M, Tabata Y, Kariya M, Hosseinkhani H, Suzuki A, et al. (2005) In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release 103: 7-19.
219. Chacko RT, Ventura J, Zhuang J, Thayumanavan S (2012) Polymer nanogels: a versatile nanoscopic drug delivery platform. Adv Drug Deliv Rev 64: 836-851.
220. Moya-Ortega MD, Alvarez-Lorenzo C, Concheiro A, Loftsson T (2012) Cyclodextrin-based nanogels for pharmaceutical and biomedical applications. Int J Pharm 428: 152-163.
221. Seo SH, Han HD, Noh KH, Kim TW, Son SW (2009) Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity. Clin Exp Metastasis 26: 179-187.
222. Sharma A, Madhunapantula SV, Robertson GP (2012) Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol 8: 47-69.
223. Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, et al. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54: 6342-6363.
224. Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R (2003) 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 14: 395-399.
225. Berhoune M, Banu E, Scotte F, Prognon P, Oudard S, et al. (2008) Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Ann Pharmacother 42: 1640-1652.
226. Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, et al. (2009) Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15: 692-700.
227. Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, et al. (2009) Drug ratio-dependent antitumor actiAvity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 8: 2266-2275.
228. Li X, Lu WL, Liang GW, Ruan GR, Hong HY, et al. (2006) Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. Eur J Clin Invest 36: 409-418.
229. Liang GW, Lu WL, Wu JW, Zhao JH, Hong HY, et al. (2008) Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundam Clin Pharmacol 22: 429-437.
230. Agrawal V, Paul MK, Mukhopadhyay AK (2005) 6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization. J Liposome Res 15: 141-155.
231. Patel NR, Rathi A, Mongayt D, Torchilin VP (2011) Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using longcirculating liposomes. Int J Pharm 416: 296-299.
232. Clementi C, Miller K, Mero A, Satchi-Fainaro R, Pasut G (2011) Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm 8: 1063-1072.
233. Tekade RK, Dutta T, Tyagi A, Bharti AC, Das BC, et al. (2008) Surfaceengineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J Drug Target 16: 758-772.
234. Ren Y, Kang CS, Yuan XB, Zhou X, Xu P, et al. (2010) Co-delivery of asmiR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 21: 303-314.
235. Lee IH, An S, Yu MK, Kwon HK, Im SH, et al. (2011) Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J Control Release 155: 435-441.
236. Song XR, Zheng Y, He G, Yang L, Luo YF, et al. (2010) Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J Pharm Sci 99: 4874-4879.
237. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, et al. (2011) Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32: 8281-8290.
238. Patil Y, Sadhukha T, Ma L, Panyam J (2009) Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136: 21-29.
239. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J (2010) The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31: 358-365.
240. Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, et al. (2009) Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30: 3466-3475.
241. Dilnawaz F, Singh A, Mohanty C, Sahoo SK (2010) Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31: 3694-3706.